Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily drink help control diabetes? new trial launches

NCT ID NCT07585630

Disease control Sponsor: University of California, Riverside Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a drink called A1Cantus can lower blood sugar levels (HbA1c) in adults with type 2 diabetes. About 50 participants will drink either the active supplement or a placebo twice daily for 3 months. The study is double-blind, meaning neither participants nor researchers know who gets the real drink.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A1Cantus drink (dietary supplement)
What this could lead to
If it works, this could offer a simple, daily drink to help control blood sugar in people with type 2 diabetes.
What could go wrong
This is a small, early-phase trial with only 50 people. The drink may not lower blood sugar better than placebo, and results may not apply to everyone with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 21 years of age or older and not older than 75 recruited from UCR Health * Clinical diagnosis of type II DM with Ha1c \>= 8 but less than or equal to 10 * Stable medications for at least 6 months * Speak Spanish and/or English * Sign an informed consent form * No other members in their household are participating in the study Exclusion Criteria: * Patients \<21 years of age, who do not have type II DM, whose Ha1c is less than 8 or \> 10, * Have major complications of diabetes, including CKD, diabetic retinopathy, ADVD risk \> 5, or history of CVD/stroke * Do not speak and understand either English or Spanish well * Allergic to cinnamon * Severe diseases, such as cancer * Compromised immune system * Eating disorders * BMI of 40 or higher * Already have a family member participating in the study * Substance use disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCR Health

    Riverside, California, 92521, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.